Annals of oncology : official journal of the European Society for Medical Oncology
-
Randomized Controlled Trial
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial comparing FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab. ⋯ NCT00433927 (ClinicalTrials.gov); AIO KRK0306 FIRE-3.
-
Letter Case Reports
Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.